CBD Denver Inc (CBDD)
OTHER OTC:CBDD
Want to see CBDD full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Product Diversification
A diverse product range allows CBD Denver to cater to various consumer preferences, enhancing market reach and reducing dependency on a single product line.
Negative Factors
High Debt Levels
High leverage and negative equity indicate financial risk, potentially limiting CBD Denver's ability to invest in growth opportunities and affecting long-term stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Diversification
A diverse product range allows CBD Denver to cater to various consumer preferences, enhancing market reach and reducing dependency on a single product line.
Read all positive factors
CBD Denver (CBDD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.07M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)78.63
Revenue Growth-16.53%
EPS Growth-100.00%
CountryUS
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustrySpecialty Retail
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,741,204,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)-2.18
Price to Sales (P/S)0.78
P/FCF Ratio-33.19
Enterprise Value/Market Cap1.90
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit10.28
Enterprise Value/Ebitda8.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CBD Denver Business Overview & Revenue Model
Company Description
CBD of Denver Inc. engages in developing and commercializing cannabidiol (CBD) products. It is involved in the research, development, and distribution of premium hemp extract products. The company was formerly known as Verde Media Group, Inc. and ...
How the Company Makes Money
CBD Denver makes money primarily through the sale of its CBD-infused products to both retail and wholesale customers. The company generates revenue by distributing its products through various channels, including online direct-to-consumer sales, p...
CBD Denver Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.42M | 3.75M | 2.98M | 2.34M | 22.85M | 15.99M |
| Gross Profit | 199.01K | 218.16K | 165.48K | -670.00K | 240.52K | 1.41M |
| EBITDA | 232.44K | 85.25K | 865.66K | -3.03M | -63.44K | 1.21M |
| Net Income | 98.44K | -79.93K | 583.58K | -3.25M | -236.00K | 779.14K |
Balance Sheet | ||||||
| Total Assets | 8.52K | 40.76K | 128.30K | 28.04K | 1.97M | 2.74M |
| Cash, Cash Equivalents and Short-Term Investments | 8.52K | 35.12K | 36.55K | 28.04K | 91.51K | 82.65K |
| Total Debt | 979.65K | 1.06M | 1.06M | 949.38K | 781.68K | 253.21K |
| Total Liabilities | 1.35M | 1.38M | 1.48M | 2.00M | 1.72M | 1.94M |
| Stockholders Equity | -1.34M | -1.34M | -1.35M | -1.97M | 247.66K | 798.37K |
Cash Flow | ||||||
| Free Cash Flow | -143.12K | -87.85K | -31.44K | -759.21K | -723.90K | 60.95K |
| Operating Cash Flow | -143.12K | -87.85K | -31.44K | -759.21K | -723.90K | 60.95K |
| Investing Cash Flow | 0.00 | 0.00 | 11.08K | 0.00 | 0.00 | -15.98K |
| Financing Cash Flow | 13.10K | 86.42K | 10.97K | 731.00K | 855.49K | 310.00 |
CBD Denver Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.07M | ― | ― | ― | -16.53% | -100.00% | |
50 Neutral | $3.25M | -0.05 | -202.20% | ― | -49.63% | 82.22% | |
48 Neutral | $8.48M | -10.73 | -40.66% | ― | -1.50% | 80.17% | |
44 Neutral | $5.39M | -0.28 | -203.36% | ― | ― | 90.53% | |
44 Neutral | $1.92M | -0.18 | -145.52% | ― | ― | 97.70% |
* Healthcare Sector Average
CBDD
CBD Denver
―
―
―
YCBD
cbdMD
0.93
-1.11
-54.41%
DRMA
Dermata Therapeutics
1.30
-6.20
-82.67%
BJDX
Bluejay Diagnostics
2.00
-4.56
-69.51%
TIVC
Tivic Health Systems
1.14
-5.90
-83.81%
CERO
CERo Therapeutics Holdings
0.03
-22.17
-99.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―